Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Adult Precursor B-ALL (HOVON-146)
NCT03541083Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jun 2018
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by HOVON. Primary endpoint: Proportion of patients achieving MRD negative response. Started Jun 2018; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03541083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541083.